Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes

BACKGROUND: In the AZA-001 trial, azacitidine (75 mg/m(2)/d subcutaneously for Days 1–7 of every 28-day cycle) demonstrated improved survival compared with conventional care regimens in patients with International Prognostic Scoring System-defined intermediate-2- or high-risk myelodysplastic syndrom...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Silverman, Lewis R., Fenaux, Pierre, Mufti, Ghulam J., Santini, Valeria, Hellström-Lindberg, Eva, Gattermann, Norbert, Sanz, Guillermo, List, Alan F., Gore, Steven D., Seymour, John F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4000012/
https://ncbi.nlm.nih.gov/pubmed/21656747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25774
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados